300639 Stock Overview
Engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Guangdong Hybribio Biotech Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.96 |
| 52 Week High | CN¥10.08 |
| 52 Week Low | CN¥4.32 |
| Beta | 0.47 |
| 11 Month Change | 10.30% |
| 3 Month Change | 23.19% |
| 1 Year Change | -29.70% |
| 33 Year Change | -45.93% |
| 5 Year Change | -28.00% |
| Change since IPO | 77.62% |
Recent News & Updates
Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
Oct 08
Is Guangdong Hybribio BiotechLtd (SZSE:300639) Using Debt In A Risky Way?
Sep 29Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) 77% Share Price Surge Not Quite Adding Up
Aug 19Recent updates
Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
Oct 08Is Guangdong Hybribio BiotechLtd (SZSE:300639) Using Debt In A Risky Way?
Sep 29Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) 77% Share Price Surge Not Quite Adding Up
Aug 19Guangdong Hybribio BiotechLtd (SZSE:300639) Is Reducing Its Dividend To CN¥0.065
May 22There May Be Some Bright Spots In Guangdong Hybribio BiotechLtd's (SZSE:300639) Earnings
May 03Shareholder Returns
| 300639 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 10.3% | -3.9% | -3.4% |
| 1Y | -29.7% | -16.5% | 6.1% |
Return vs Industry: 300639 underperformed the CN Biotechs industry which returned -16.5% over the past year.
Return vs Market: 300639 underperformed the CN Market which returned 6.1% over the past year.
Price Volatility
| 300639 volatility | |
|---|---|
| 300639 Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 300639's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300639's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 2,485 | Jianyu Wang | www.hybribio.cn |
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal.
Guangdong Hybribio Biotech Co.,Ltd. Fundamentals Summary
| 300639 fundamental statistics | |
|---|---|
| Market cap | CN¥4.43b |
| Earnings (TTM) | -CN¥293.55m |
| Revenue (TTM) | CN¥864.07m |
5.1x
P/S Ratio-15.1x
P/E RatioIs 300639 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300639 income statement (TTM) | |
|---|---|
| Revenue | CN¥864.07m |
| Cost of Revenue | CN¥397.77m |
| Gross Profit | CN¥466.30m |
| Other Expenses | CN¥759.85m |
| Earnings | -CN¥293.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 53.97% |
| Net Profit Margin | -33.97% |
| Debt/Equity Ratio | 1.6% |
How did 300639 perform over the long term?
See historical performance and comparison